Imetelstat

Geron Reports Presentations at American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 14, 2021
Research, Hospitals, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, U.S. Securities and Exchange Commission, ESA, Poster, AML, Survival, LSCS, Company, Azacitidine, MOA, MDS, ESAS, LSC, Population, RBC, Private Securities Litigation Reform Act, Nasdaq, Erythropoiesis-stimulating agent, Acute myeloid leukemia, Immortalised cell line, PDX, Lymphatic system, Thrombocytopenia, Risk, Pharmacokinetics, Malignancy, Nominal interest rate, Geron Corporation, Safety, Patient, MF, Microdeletion syndrome, Disease, Security (finance), Telomerase, Imetelstat, JAK, Vii, Fast Track, ASH, PD, Apoptosis, Mouse, Society, Corporation, Vaccine, Pharmaceutical industry, Medicine, Imetelstat, Geron, IMETELSTAT, GERON

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced three poster presentations related to imetelstat, the Companys first in class telomerase inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced three poster presentations related to imetelstat, the Companys first in class telomerase inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting.
  • We believe the unique telomerase inhibition MOA of imetelstat has the potential to transform the standard of care in hematologic malignancies.
  • Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Geron Announces Appointment of Chief Business Officer

Retrieved on: 
Thursday, December 2, 2021
Research, General Health, Pharmaceutical, Oncology, Hospitals, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, FDA, Health, Other Science, Patient, Private Securities Litigation Reform Act, Rensselaer Polytechnic Institute, Security (finance), Disease, Industry, Company, Achievement, Lymphatic system, Strategic planning, Geron Corporation, Engineering, Inflammation, MIT Sloan School of Management, U.S. Securities and Exchange Commission, JAK, Imetelstat, Chiron Corporation, MDS, Physician, Business operations, MF, Nasdaq, Machine learning, Risk, Corporation, Massachusetts Institute of Technology, Fast Track, Massachusetts, FDA, Corporate development, Merck & Co., Therapy, Infection, Employment, Novartis, Degenerative disease, Microdeletion syndrome, Apoptosis, COVID, Management, Pharmaceutical industry, Imetelstat, Geron, IMETELSTAT, GERON

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer.
  • Ed Kovals business development expertise, extensive industry network and successful track record in corporate deal-making further strengthens our executive team, said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
  • Mr. Koval will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities.
  • In connection with Mr. Kovals appointment as Chief Business Officer, Melissa Kelly Behrs has been appointed Executive Vice President, Business Operations, and Chief Alliance Officer, and will continue to serve on the Executive Management Committee and report to Dr. Scarlett.

Geron Presents Investor Event Highlights

Retrieved on: 
Tuesday, November 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, AML, Security (finance), COVID-19, Vii, Azacitidine, Ruxolitinib, Imetelstat, IMPRESS, Geron Corporation, Fast Track, Risk, Lists of people executed in the United States, Safety, Microdeletion syndrome, Investor relations, Asterias, Acute myeloid leukemia, Research, HIV disease progression rates, JAK, U.S. Securities and Exchange Commission, Event, Corporation, Survival, Patient, Lineage Cell Therapeutics, Private Securities Litigation Reform Act, Disease, Income, Union, HMA, RBC, Lymphatic system, LR, Pharmacokinetics, Apoptosis, MD Anderson Cancer Center, Venetoclax, European Union, Â, MDS, Company, Telomerase, Fibrosis, Nasdaq, Intellectual property, ESA, Pharmaceutical industry, Vaccine, Lithium, Health insurance, Imetelstat, IMerge Phase 3, IMpactMF, Geron, IMETELSTAT, IMERGE PHASE 3, IMPACTMF, GERON

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, summarized key highlights from its Investor Event held on November 9.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, summarized key highlights from its Investor Event held on November 9.
  • An archive of the presentation webcast is available through the Investor Relations section of Gerons website under Events.
  • At the Investor Event, key opinion leaders (KOLs) in the treatment of hematologic malignancies presented their views on the current unmet medical needs in these diseases.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Safety, Corporation, 2021 Essex County Council election, Annual, PD, Disease, MDS, Survival, Abstract (summary), ESAS, Fast Track, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Security (finance), Cytopenia, Lymphatic system, Immortalised cell line, Apoptosis, ASH, LSCS, Risk, Geron Corporation, Azacitidine, LSC, Microdeletion syndrome, Company, Erythropoiesis-stimulating agent, Acute myeloid leukemia, JAK, Proceedings of the Human Factors and Ergonomics Society Annual Meeting, Nasdaq, AML, MF, PDX, Mouse, Liver, Society, Nominal interest rate, Pharmaceutical industry, Vaccine, Imetelstat, Geron, IMETELSTAT, GERON

We look forward to continued work in these areas as we expand the potential applications for imetelstat in hematologic malignancies.

Key Points: 
  • We look forward to continued work in these areas as we expand the potential applications for imetelstat in hematologic malignancies.
  • In accordance with ASH policies, abstracts submitted to the ASH Annual Meeting are embargoed from the time of submission.
  • To be eligible for presentation at the ASH Annual Meeting, any additional data or information to be presented at the Annual Meeting may not be made public before the presentation.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat

Retrieved on: 
Monday, October 25, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Safety, Disease, Health care, Cytopenia, SMC, United Kingdom, National Health Service, Clinical trial, COVID-19, JAK, National Institute, Cytogenetics, RBC, NICE, Quality of life, Diagnosis, Survival, Security (finance), Private Securities Litigation Reform Act, Apoptosis, Frexit, Company, TDP, Acute leukemia, Intellectual property, Iron overload, MAA, Corporation, Innovation, Healthcare Improvement Scotland, MDS, Medication, Fast Track, Marketing, Lymphatic system, Risk, Medicine, Geron Corporation, Chromosome, Microdeletion syndrome, Public health, Nasdaq, MHRA, MF, Heart, Patient, Bone marrow, NHS, Myelodysplastic syndrome, ESA, National Institute for Health and Care Excellence, Pharmaceutical industry, ILAP and Innovation Passport, IMerge Phase 3, Myelodysplastic Syndromes, Imetelstat, Geron, ILAP AND INNOVATION PASSPORT, IMERGE PHASE 3, MYELODYSPLASTIC SYNDROMES, IMETELSTAT, GERON

The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines.

Key Points: 
  • The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines.
  • Imetelstat is currently being studied in two Phase 3 clinical trials, IMerge Phase 3 in lower risk MDS and IMpactMF in refractory myelofibrosis.
  • Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in myeloid hematologic malignancies.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Retrieved on: 
Monday, October 18, 2021
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, General Health, Health, Clinical Trials, Lymphatic system, Patient, ESA, International Prognostic Scoring System, Diagnosis, Bone marrow, Private Securities Litigation Reform Act, Geron Corporation, Nasdaq, Achievement, Heart, Risk, Imetelstat, Microdeletion syndrome, Corporation, Security (finance), MDS, JAK, RBC, Disease, Cytogenetics, Myelodysplastic syndrome, Clinical trial, Acute leukemia, Iron overload, Intellectual property, U.S. Securities and Exchange Commission, Company, Fast Track, Apoptosis, Safety, Chromosome, ESAS, Quality of life, Cytopenia, COVID-19, Pharmaceutical industry, IMerge Phase 3, Myelodysplastic Syndromes, Imetelstat, Geron, IMERGE PHASE 3, MYELODYSPLASTIC SYNDROMES, IMETELSTAT, GERON

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
  • Completing patient enrollment in IMerge Phase 3 brings us one step closer to delivering imetelstat as a potential treatment alternative for patients with lower risk MDS who are relapsed or refractory to ESAs.
  • IMerge Phase 3 is a double-blind, randomized, placebo-controlled Phase 3 clinical trial with registrational intent.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Geron to Host a Virtual Investor Event in November

Retrieved on: 
Friday, October 15, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Division, MD Anderson Cancer Center, Mount Sinai, Hematology, Investor relations, Geron Corporation, Nasdaq, Risk, Icahn School of Medicine at Mount Sinai, Microdeletion syndrome, Corporation, Department, Clinic, Event, Webcast, Teaching hospital, Clinical Lymphoma, Myeloma & Leukemia, Company, University, Imetelstat, Cell therapy, Associate, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m.
  • Topics to be covered at the event, include:
    The unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis and the disease modification potential of imetelstat, Gerons first-in-class telomerase inhibitor.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in myeloid hematologic malignancies.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

Retrieved on: 
Monday, October 11, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, Company, Private Securities Litigation Reform Act, Fatigue, Patient, Pharmacokinetics, Publication, Risk, Fibrosis, MDS, Microdeletion syndrome, Department, Real world data, BAT, Fast Track, H. Lee Moffitt Cancer Center & Research Institute, MF, Survival, Blood, Safety, Bone marrow, Apoptosis, OS, RWD, Population, Itch, Imetelstat, Geron Corporation, U.S. Securities and Exchange Commission, Real, Lymphatic system, ESA, Security (finance), Hematology, Myeloproliferative neoplasm, Bone pain, Corporation, Fever, Disease, JAK, Primary myelofibrosis, Abdominal pain, Nasdaq, Pharmaceutical industry, Myelofibrosis (MF), Imetelstat, Geron, MYELOFIBROSIS (MF), IMETELSTAT, GERON

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the publication in the Annals of Hematology of a paper entitled Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data, which details statistical analyses comparing data from the Companys IMbark Phase 2 clinical trial to closely matched Real World Data (RWD).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the publication in the Annals of Hematology of a paper entitled Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data, which details statistical analyses comparing data from the Companys IMbark Phase 2 clinical trial to closely matched Real World Data (RWD).
  • The paper describes several statistical adjustment methods and multiple sensitivity analyses to improve comparability of the data set from the Companys IMbark Phase 2 trial and RWD to mimic the effect of a randomized trial.
  • While acknowledging the limitations of RWD analyses, the authors conclude that the results of these analyses warrant further prospective evaluation of imetelstat in a Phase 3 setting with OS as a primary endpoint.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023

Retrieved on: 
Monday, August 16, 2021
Biotechnology, Pharmaceutical, Health, U.S. Securities and Exchange Commission, Clinical trial, Refractory, Achievement, European Hematology Association, Asterias, Ix, Research, Journal, RBC, ESA, Safety, Apoptosis, Corporation, Xi, Company, Private Securities Litigation Reform Act, Journal of Clinical Oncology, Relapse, Risk, Telephone, Geron Corporation, Lineage Cell Therapeutics, Microdeletion syndrome, LR, ID, JAK, Register, Fast Track, IDMC, Â, COVID-19, Pharmacokinetics, Bone marrow, MDS, Telomerase, Income, Intellectual property, OS, Disease, Survival, Patient, Webcast, Security (finance), EHA, Nasdaq, Vii, Pharmaceutical industry, Health insurance, Medical imaging, Vaccine, Lithium, Medicine, Imetelstat, IMerge Phase 3, IMpactMF, Geron, IMETELSTAT, IMERGE PHASE 3, IMPACTMF, GERON

In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023, said John A. Scarlett, M.D., Chairman and Chief Executive Officer.

Key Points: 
  • In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023, said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
  • As of August 12, 2021, the Company had achieved 91% of the planned enrollment in IMerge Phase 3.
  • With the revised 12-month follow-up period for the primary analysis, the Company now projects that top-line results from IMerge Phase 3 will be available in the first quarter of 2023.
  • For further information about IMerge Phase 3, including enrollment criteria, locations, and current status, please visit ClinicalTrials.gov/NCT02598661.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, July 22, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Financial markets, Branches of biology, Finance, Stem cells, Corporate finance, Geron Corporation, Stock market, Imetelstat, Telomerase, Stock, NASDAQ, Geron

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on July 21, 2021 at an exercise price of $1.33 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.